

Confidentiality Note:

The information contained in this facsimile message is confidential and its contents are intended to be legally privileged information solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the address shown below via air courier service, the United States Postal Service or your national postal service (air mail). Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604

919-862-2200
Fax: 919-862-2260

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

DATE: January 31, 2002

TO: Examiner Hope Robinson

FROM: Leslie T. Henry

Application Serial No. 09/385,114; filed August 27, 1999

NO. OF PAGES: 18
(Including cover page)

OPERATOR:

PS # 07002 - #1

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT (919) 862-2221

USER CODE: BURTP

FAX NUMBER: (703) 308-4242

CLIENT/MATTER: 035784/205462

REQUESTED BY: Polly Burton, Ext. 2277

VOICE NUMBER: (703) 308-6231

*Please enter
1/31/02*

D

Attorney's Docket No. 1543.004 (5784-81)**RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED
PROCEDURE - EXAMINING GROUP 1653****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Whitehouse
Appl. No.: 09/385,114
Filed: August 27, 1999
For: ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2
AND METHOD OF USE

Confirmation No.: None assigned
Group Art Unit: 1653
Examiner: H. Robinson

January 31, 2002

BOX AF
Commissioner for Patents
Washington, DC 20231

**SUPPLEMENTAL AMENDMENT AFTER FINAL ACTION
PURSUANT TO 37 C.F.R. § 1.116**

Sir:

Responsive to the telephone conversation with the Examiner on January 30, 2002, and supplemental to the Amendment filed January 7, 2002, in response to the Final Office Action of September 7, 2001, reexamination and reconsideration of the above-identified application are requested in view of the following amendments and remarks.

The Examiner is respectfully requested to enter the following amendments.

In the Claims:

Please amend claims 10, 12-18, 24, 26, 27, 30, 32, 35, 38, 44, 46-52, 56, 58, 59, 62, 64, and 65 to read as follows:

1. (twice amended) A method for treating a human patient for coronary artery disease, comprising administering a therapeutically effective amount of a recombinant FGF-2 or an angiogenically active fragment or an angiogenically active mutein thereof into one or more

01/11/2002

00000001

1

115

\$110.00 01/08/2002

DA 160605